Patent · US Active

Methods and compositions related to T-cell activity

US9944992B2 · kind B2 · utility

3Cited by
2References
12Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMar 14, 2014
Grant dateApr 17, 2018
Priority date
Expiry dateMar 14, 2034

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY02A90/10
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Embodiments concern methods and composition related to anergic T-cells in patients, such as cancer patients. T cell anergy is a hyporesponsive state induced by TCR engagement in the absence of costimulation (Schwartz, 2003). Anergy induction was initially observed in vitro using chemically-fixed antigen presenting cells (APCs). Subsequently, it was found that anergy could be induced by immobilized anti-CD3 mAb or calcium ionophores (such as ionomycin) in vitro, and by superantigen and soluble antigenic peptide in vivo. Indirect evidence has suggested that T cell dysfunction in the tumor microenvironment and establishment of transplant tolerance is partially due to T cell anergy (Gajewski et al., 2011).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.